Sign in or create an account to add this stock to your watchlist.
About OncoMed Pharmaceuticals (NASDAQ:OMED)
OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. The company's product candidates and preclinical programs include navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors, as well as in two Phase Ib clinical trials for patients with platinum-resistant ovarian cancer and metastatic colorectal cancer; anti-TIGIT (OMP-313M32), a T-cell immunoreceptor with immunoglobulin and ITIM domain, which is in Phase Ia clinical trial for patients with advanced or metastatic solid tumors; GITRL-Fc (OMP-336B11), a glucocorticoid-induced tumor necrosis factor receptor -related protein and its ligand, which is in Phase Ia clinical trial for patients with advanced or metastatic solid tumors; and rosmantuzumab (anti-RSPO3, OMP-131R10), a monoclonal antibody targeting the RSPO-LGR CSC pathway. It has strategic alliances with Celgene Corporation for discovery, development, and commercialization of novel small molecule therapeutics; and Bayer Pharma AG for discovery, development, and commercialization of anti- cancer stem cell biologic and small molecule therapeutics targeting the Wnt signaling pathway. OncoMed Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Redwood City, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OMED
CUSIPN/A
Phone650-995-8200
Debt
Debt-to-Equity RatioN/A
Current Ratio2.59
Quick Ratio2.59
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$38.15 million
Price / Sales2.86
Cash FlowN/A
Price / CashN/A
Book Value($1.28) per share
Price / Book-2.22
Profitability
EPS (Most Recent Fiscal Year)($1.04)
Net Income$-39,060,000.00
Net Margins-55.36%
Return on EquityN/A
Return on Assets-18.94%
Miscellaneous
Employees56
Outstanding Shares38,430,000
OncoMed Pharmaceuticals (NASDAQ:OMED) Frequently Asked Questions
What is OncoMed Pharmaceuticals' stock symbol?
OncoMed Pharmaceuticals trades on the NASDAQ under the ticker symbol "OMED."
How were OncoMed Pharmaceuticals' earnings last quarter?
OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) posted its quarterly earnings data on Tuesday, May, 8th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.07. The biopharmaceutical company had revenue of $7.85 million for the quarter, compared to analyst estimates of $7.27 million. View OncoMed Pharmaceuticals' Earnings History.
When is OncoMed Pharmaceuticals' next earnings date?
What price target have analysts set for OMED?
5 brokerages have issued 12-month target prices for OncoMed Pharmaceuticals' shares. Their predictions range from $3.00 to $6.00. On average, they expect OncoMed Pharmaceuticals' stock price to reach $4.60 in the next twelve months. View Analyst Ratings for OncoMed Pharmaceuticals.
Who are some of OncoMed Pharmaceuticals' key competitors?
Some companies that are related to OncoMed Pharmaceuticals include Innate Pharma (IPHYF), Mersana Therapeutics (MRSN), Zymeworks (ZYME), Sinovac Biotech (SVA), GTX (GTXI), Clearside Biomedical (CLSD), ProMetic Life Sciences (PFSCF), Kala Pharmaceuticals (KALA), MediciNova (MNOV), Merus (MRUS), Synergy Pharmaceuticals (SGYP), American Brivision (Holding) (ABVC), Syros Pharmaceuticals (SYRS), Cara Therapeutics (CARA) and Albireo (ALBO).
Who are OncoMed Pharmaceuticals' key executives?
OncoMed Pharmaceuticals' management team includes the folowing people:
- Mr. Perry A. Karsen, Exec. Chairman (Age 63)
- Dr. John A. Lewicki, Pres, CEO & Director (Age 66)
- Ms. Yvonne Li, VP of Fin. & Admin. and Controller
- Dr. Austin Gurney Ph.D., Chief Scientific Officer & Sr. VP (Age 54)
- Dr. Alicia J. Hager J.D., Ph.D., Sr. VP and Gen. Counsel (Age 48)
Has OncoMed Pharmaceuticals been receiving favorable news coverage?
News headlines about OMED stock have trended positive on Monday, Accern Sentiment reports. Accern scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. OncoMed Pharmaceuticals earned a news impact score of 0.48 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 46.62 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are OncoMed Pharmaceuticals' major shareholders?
OncoMed Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BVF Inc. IL (11.07%), Millennium Management LLC (0.61%), Spark Investment Management LLC (0.30%), Birchview Capital LP (0.26%), Sofinnova Ventures Inc (0.17%) and DRW Securities LLC (0.14%). Company insiders that own OncoMed Pharmaceuticals stock include Alicia J Hager, Jack W Lasersohn, John A Lewicki, Jonathan D Root, Paul J Hastings, Perry A Karsen, Sunil Patel, Timothy Hoey and Yvonne Li. View Institutional Ownership Trends for OncoMed Pharmaceuticals.
Which major investors are selling OncoMed Pharmaceuticals stock?
OMED stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and BVF Inc. IL. Company insiders that have sold OncoMed Pharmaceuticals company stock in the last year include Alicia J Hager, John A Lewicki, Jonathan D Root, Paul J Hastings and Yvonne Li. View Insider Buying and Selling for OncoMed Pharmaceuticals.
Which major investors are buying OncoMed Pharmaceuticals stock?
OMED stock was bought by a variety of institutional investors in the last quarter, including Birchview Capital LP, Sofinnova Ventures Inc, Spark Investment Management LLC and DRW Securities LLC. Company insiders that have bought OncoMed Pharmaceuticals stock in the last two years include Jack W Lasersohn and Perry A Karsen. View Insider Buying and Selling for OncoMed Pharmaceuticals.
How do I buy shares of OncoMed Pharmaceuticals?
Shares of OMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OncoMed Pharmaceuticals' stock price today?
One share of OMED stock can currently be purchased for approximately $2.84.
How big of a company is OncoMed Pharmaceuticals?
OncoMed Pharmaceuticals has a market capitalization of $109.14 million and generates $38.15 million in revenue each year. The biopharmaceutical company earns $-39,060,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis. OncoMed Pharmaceuticals employs 56 workers across the globe.
How can I contact OncoMed Pharmaceuticals?
OncoMed Pharmaceuticals' mailing address is 800 Chesapeake Drive, Redwood City CA, 94063. The biopharmaceutical company can be reached via phone at 650-995-8200 or via email at [email protected]
MarketBeat Community Rating for OncoMed Pharmaceuticals (OMED)
MarketBeat's community ratings are surveys of what our community members think about OncoMed Pharmaceuticals and other stocks. Vote "Outperform" if you believe OMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
OncoMed Pharmaceuticals (NASDAQ:OMED) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for OncoMed Pharmaceuticals in the last 12 months. Their average twelve-month price target is $4.60, suggesting that the stock has a possible upside of 61.97%. The high price target for OMED is $6.00 and the low price target for OMED is $3.00. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.20 | 2.20 | 2.25 | 2.25 |
| Ratings Breakdown: | 0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $4.60 | $4.60 | $6.00 | $6.00 |
| Price Target Upside: | 61.97% upside | 49.35% upside | 50.75% upside | 37.30% upside |
OncoMed Pharmaceuticals (NASDAQ:OMED) Consensus Price Target History
OncoMed Pharmaceuticals (NASDAQ:OMED) Analyst Ratings History
Show:
(Data available from 5/21/2016 forward)
OncoMed Pharmaceuticals (NASDAQ:OMED) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
OncoMed Pharmaceuticals (NASDAQ OMED) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 20.32%
Institutional Ownership Percentage: 49.52%
OncoMed Pharmaceuticals (NASDAQ OMED) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/24/2018 | Alicia J. Hager | SVP | Sell | 4,051 | $2.68 | $10,856.68 | |  |
| 4/24/2018 | John A. Lewicki | CEO | Sell | 4,557 | $2.68 | $12,212.76 | | |
| 4/24/2018 | Yvonne Li | Insider | Sell | 5,062 | $2.68 | $13,566.16 | | |
| 10/10/2017 | Alicia J Hager | SVP | Sell | 1,248 | $4.24 | $5,291.52 | | |
| 10/10/2017 | Paul J Hastings | CEO | Sell | 1,398 | $4.24 | $5,927.52 | | |
| 6/5/2017 | Perry A Karsen | Director | Buy | 10,000 | $3.46 | $34,600.00 | 10,000 | |
| 5/26/2017 | Jonathan D Root | Director | Sell | 13,880 | $3.71 | $51,494.80 | 121,020 | |
| 5/25/2017 | Jack W Lasersohn | Director | Buy | 34,614 | $3.37 | $116,649.18 | 185,709 | |
| 5/23/2017 | Jack W Lasersohn | Director | Buy | 20,000 | $3.55 | $71,000.00 | 151,095 | |
| 5/19/2017 | Jonathan D Root | Director | Sell | 7,487 | $3.70 | $27,701.90 | 121,020 | |
| 5/16/2017 | Jack W Lasersohn | Director | Buy | 23,507 | $3.49 | $82,039.43 | 131,095 | |
| 4/4/2017 | Alicia J. Hager | SVP | Sell | 4,316 | $9.06 | $39,102.96 | | |
| 4/4/2017 | Paul J. Hastings | CEO | Sell | 6,473 | $9.06 | $58,645.38 | | |
| 4/4/2017 | Sunil Patel | Insider | Sell | 5,754 | $9.06 | $52,131.24 | | |
| 1/6/2017 | Paul J. Hastings | CEO | Sell | 42,738 | $8.34 | $356,434.92 | | |
| 1/3/2017 | John A. Lewicki | EVP | Sell | 9,175 | $7.63 | $70,005.25 | | |
| 1/3/2017 | Timothy Hoey | SVP | Sell | 12,763 | $7.64 | $97,509.32 | | |
| 1/11/2016 | Jakob Dupont | SVP | Sell | 2,500 | $20.01 | $50,025.00 | 20,642 | |
| 1/7/2016 | Alicia J. Hager | VP | Sell | 1,623 | $22.28 | $36,160.44 | 13,377 | |
| 1/7/2016 | John A. Lewicki | EVP | Sell | 2,162 | $22.28 | $48,169.36 | 17,838 | |
| 1/6/2016 | Paul J. Hastings | CEO | Sell | 2,412 | $22.28 | $53,739.36 | 22,025 | |
| 11/27/2015 | Alicia J. Hager | VP | Sell | 1,800 | $23.14 | $41,652.00 | 15,000 | |
| 10/27/2015 | Alicia J. Hager | VP | Sell | 5,400 | $21.00 | $113,400.00 | 15,000 | |
| 10/26/2015 | Austin Gurney | Insider | Sell | 14,000 | $20.00 | $280,000.00 | 35,419 | |
| 10/26/2015 | Jakob Dupont | SVP | Sell | 5,000 | $20.00 | $100,000.00 | 22,804 | |
| 9/30/2015 | Jack W. Lasersohn | Director | Buy | 11,210 | $16.01 | $179,472.10 | 46,560 | |
| 9/29/2015 | Jack W. Lasersohn | Director | Buy | 3,140 | $14.15 | $44,431.00 | 35,350 | |
| 9/28/2015 | Jack W. Lasersohn | Director | Buy | 10,000 | $14.74 | $147,400.00 | 35,350 | |
| 7/10/2015 | Jakob Dupont | SVP | Sell | 2,500 | $20.13 | $50,325.00 | | |
| 7/6/2015 | Jakob Dupont | SVP | Sell | 2,500 | $21.22 | $53,050.00 | | |
| 6/29/2015 | Alicia J Hager | VP | Sell | 1,800 | $22.67 | $40,806.00 | | |
| 6/22/2015 | Timothy Hoey | SVP | Sell | 5,000 | $26.07 | $130,350.00 | | |
| 6/16/2015 | John A Lewicki | EVP | Sell | 17,000 | $25.07 | $426,190.00 | | |
| 6/15/2015 | John A Lewicki | EVP | Sell | 8,500 | $24.92 | $211,820.00 | | |
| 5/27/2015 | Alicia J Hager | VP | Sell | 1,800 | $23.07 | $41,526.00 | | |
| 5/18/2015 | Austin Gurney | Insider | Sell | 4,000 | $22.48 | $89,920.00 | | |
| 4/27/2015 | Alicia J Hager | VP | Sell | 1,800 | $25.65 | $46,170.00 | | |
| 4/27/2015 | Timothy Hoey | SVP | Sell | 6,887 | $25.65 | $176,651.55 | | |
| 4/17/2015 | Austin Gurney | Insider | Sell | 4,000 | $25.51 | $102,040.00 | | |
| 4/10/2015 | Jakob Dupont | SVP | Sell | 1,500 | $26.51 | $39,765.00 | | |
| 4/2/2015 | John A Lewicki | EVP | Sell | 17,000 | $25.28 | $429,760.00 | | |
| 3/20/2015 | Sunil Patel | Insider | Sell | 18,000 | $27.76 | $499,680.00 | | |
| 3/17/2015 | Austin Gurney | Insider | Sell | 4,000 | $27.37 | $109,480.00 | | |
| 2/5/2015 | Timothy Hoey | SVP | Sell | 7,500 | $22.83 | $171,225.00 | | |
| 2/2/2015 | John A Lewicki | EVP | Sell | 4,000 | $22.49 | $89,960.00 | | |
| 1/20/2015 | Austin Gurney | Insider | Sell | 4,000 | $22.87 | $91,480.00 | | |
| 1/12/2015 | Jakob Dupont | SVP | Sell | 1,500 | $25.89 | $38,835.00 | | |
| 1/5/2015 | Jakob Dupont | SVP | Sell | 7,500 | $23.00 | $172,500.00 | | |
| 1/2/2015 | John A Lewicki | EVP | Sell | 4,000 | $22.10 | $88,400.00 | | |
| 12/31/2014 | Denise Pollard-Knight | Director | Sell | 3,799 | $21.66 | $82,286.34 | | |
| 12/30/2014 | Denise Pollard-Knight | Director | Sell | 17,607 | $21.63 | $380,839.41 | | |
| 12/18/2014 | Jonathan D Root | Director | Sell | 13,052 | $21.05 | $274,744.60 | | |
| 12/17/2014 | Austin Gurney | Insider | Sell | 4,000 | $20.00 | $80,000.00 | | |
| 12/10/2014 | Denise Pollard-Knight | Director | Sell | 32,940 | $21.78 | $717,433.20 | | |
| 12/9/2014 | Denise Pollard-Knight | Director | Sell | 23,273 | $21.78 | $506,885.94 | | |
| 12/8/2014 | Denise Pollard-Knight | Director | Sell | 1,727 | $21.68 | $37,441.36 | | |
| 12/5/2014 | Denise Pollard-Knight | Director | Sell | 25,000 | $21.60 | $540,000.00 | | |
| 12/1/2014 | John A Lewicki | EVP | Sell | 4,000 | $21.19 | $84,760.00 | | |
| 11/5/2014 | Timothy Hoey | SVP | Sell | 2,500 | $19.51 | $48,775.00 | | |
| 10/29/2014 | Paul J Hastings | CEO | Sell | 16,769 | $21.99 | $368,750.31 | | |
| 10/2/2014 | Austin Gurney | Insider | Sell | 4,000 | $20.00 | $80,000.00 | | |
| 10/2/2014 | John A Lewicki | EVP | Sell | 5,809 | $20.00 | $116,180.00 | | |
| 9/4/2014 | Jack W Lasersohn | Director | Buy | 3,170 | $18.35 | $58,169.50 | | |
| 9/3/2014 | Jack W Lasersohn | Director | Buy | 3,000 | $18.40 | $55,200.00 | | |
| 9/2/2014 | John A Lewicki | EVP | Sell | 2,191 | $20.01 | $43,841.91 | | |
| 8/22/2014 | Austin Gurney | Insider | Sell | 4,000 | $20.00 | $80,000.00 | | |
| 8/21/2014 | Deepika Pakianathan | Director | Buy | 80,203 | $18.98 | $1,522,252.94 | | |
| 8/15/2014 | Jack W Lasersohn | Director | Buy | 1,045 | $17.00 | $17,765.00 | | |
| 8/5/2014 | Timothy Hoey | SVP | Sell | 2,500 | $21.66 | $54,150.00 | | |
| 8/1/2014 | John A Lewicki | EVP | Sell | 4,000 | $20.98 | $83,920.00 | | |
| 7/29/2014 | Paul J Hastings | CEO | Sell | 16,770 | $22.11 | $370,784.70 | | |
| 7/23/2014 | Jakob Dupont | SVP | Sell | 1,500 | $23.00 | $34,500.00 | | |
| 7/17/2014 | Austin Gurney | Insider | Sell | 4,000 | $20.46 | $81,840.00 | | |
| 7/1/2014 | John A Lewicki | EVP | Sell | 4,000 | $23.86 | $95,440.00 | | |
| 6/30/2014 | Denise Pollard-Knight | Director | Sell | 11,485 | $23.59 | $270,931.15 | | |
| 6/26/2014 | Jakob Dupont | SVP | Sell | 1,500 | $23.00 | $34,500.00 | | |
| 6/25/2014 | Denise Pollard-Knight | Director | Sell | 3,252 | $23.56 | $76,617.12 | | |
| 6/24/2014 | Denise Pollard-Knight | Director | Sell | 64,561 | $24.08 | $1,554,628.88 | | |
| 6/17/2014 | Austin Gurney | Insider | Sell | 4,000 | $24.99 | $99,960.00 | | |
| 6/16/2014 | John A Lewicki | EVP | Sell | 4,000 | $24.59 | $98,360.00 | | |
| 6/10/2014 | Presidio Management Group Viii | Major Shareholder | Sell | 13,052 | $24.57 | $320,687.64 | | |
| 5/12/2014 | Presidio Management Group Viii | major shareholder | Sell | 46,327 | $21.99 | $1,018,730.73 | | |
| 7/23/2013 | Denise Pollard-Knight | Director | Buy | 58,824 | $17.00 | $1,000,008.00 | | |
| 7/23/2013 | Presidio Management Group Viii | Major Shareholder | Buy | 158,823 | $17.00 | $2,699,991.00 | | |
(Data available from 1/1/2013 forward)
OncoMed Pharmaceuticals (NASDAQ OMED) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | OncoMed Pharmaceuticals (OMED) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - May 17 at 11:45 AM |
| OncoMed Pharmaceuticals, Inc. (OMED) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - May 14 at 8:39 AM |
| Jefferies Group Weighs in on OncoMed Pharmaceuticals, Inc.'s Q2 2018 Earnings (OMED)
www.americanbankingnews.com - May 14 at 2:01 AM |
| OncoMed Pharmaceuticals, Inc. (OMED) Expected to Post Quarterly Sales of $7.04 Million
www.americanbankingnews.com - May 10 at 3:48 AM |
| OncoMed Pharmaceuticals (OMED) Releases Earnings Results
www.americanbankingnews.com - May 9 at 8:52 PM |
 | OncoMed Announces First Quarter 2018 Financial Results and Operational Highlights
finance.yahoo.com - May 9 at 9:54 AM |
| OncoMed: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 9:54 AM |
| -$0.25 EPS Expected for OncoMed Pharmaceuticals, Inc. (OMED) This Quarter
www.americanbankingnews.com - May 8 at 3:12 PM |
| Acorda (ACOR) Q1 Earnings Miss Estimates, Sales Down Y/Y
finance.yahoo.com - May 3 at 4:05 PM |
| OncoMed Pharmaceuticals (OMED) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - May 2 at 10:58 PM |
| OncoMed Pharmaceuticals to Report First Quarter 2018 Financial Results and Operational Highlights on May 8th, 2018
finance.yahoo.com - May 1 at 9:50 AM |
| Allergan (AGN) Q1 Earnings Beat Estimates, Sales Up Y/Y
finance.yahoo.com - April 30 at 4:07 PM |
| OncoMed Pharmaceuticals (OMED) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - April 30 at 9:25 AM |
| OncoMed Pharmaceuticals, Inc. (OMED) Insider Sells $13,566.16 in Stock
www.americanbankingnews.com - April 26 at 7:46 PM |
| John A. Lewicki Sells 4,557 Shares of OncoMed Pharmaceuticals, Inc. (OMED) Stock
www.americanbankingnews.com - April 26 at 7:46 PM |
| OncoMed Pharmaceuticals, Inc. (OMED) SVP Alicia J. Hager Sells 4,051 Shares
www.americanbankingnews.com - April 26 at 7:46 PM |
| Zacks: Analysts Expect OncoMed Pharmaceuticals, Inc. (OMED) Will Post Quarterly Sales of $6.51 Million
www.americanbankingnews.com - April 23 at 4:14 AM |
| -$0.24 EPS Expected for OncoMed Pharmaceuticals, Inc. (OMED) This Quarter
www.americanbankingnews.com - April 21 at 11:12 AM |
| OncoMed Pharmaceuticals (OMED) Given a $5.00 Price Target by Piper Jaffray Analysts
www.americanbankingnews.com - April 19 at 12:16 PM |
 | OncoMed Pharma (OMED) Presents Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at AACR
www.streetinsider.com - April 19 at 10:07 AM |
| OncoMed Pharmaceuticals, Inc. (OMED) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 19 at 9:13 AM |
| OncoMed Presents Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 18 at 10:06 AM |
| OncoMed to Present Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 9 at 10:21 AM |
| $6.51 Million in Sales Expected for OncoMed Pharmaceuticals, Inc. (OMED) This Quarter
www.americanbankingnews.com - April 6 at 3:42 AM |
| -$0.24 Earnings Per Share Expected for OncoMed Pharmaceuticals, Inc. (OMED) This Quarter
www.americanbankingnews.com - April 4 at 11:46 AM |
| Oncomed Pharmaceuticals (OMED) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - April 1 at 11:52 AM |
| Oncomed Pharmaceuticals (OMED) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - March 31 at 9:24 PM |
| Can The Uptrend Continue for OncoMed Pharmaceuticals (OMED)?
finance.yahoo.com - March 27 at 4:11 PM |
| Oncomed Pharmaceuticals Inc (OMED) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 25 at 7:58 AM |
| $6.51 Million in Sales Expected for Oncomed Pharmaceuticals Inc (OMED) This Quarter
www.americanbankingnews.com - March 20 at 5:52 AM |
 | BRIEF-OncoMed Announces Appointment Of John Lewicki As CEO
www.reuters.com - March 19 at 4:14 PM |
| OncoMed Announces Appointment of John Lewicki, PhD, as President, Chief Executive Officer and a member of the Board of Directors
finance.yahoo.com - March 19 at 10:36 AM |
| Oncomed Pharmaceuticals (OMED) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 17 at 11:46 PM |
| OncoMed Pharmaceuticals Inc (NASDAQ:OMED): What Are The Future Prospects?
finance.yahoo.com - March 16 at 4:13 PM |
| Catalyst Pharmaceuticals Inc (CPRX) and Achillion Pharmaceuticals, Inc. (ACHN) Among Five Cheap Healthcare Stocks To Buy Now
finance.yahoo.com - March 14 at 4:08 PM |
| HC Wainwright Reaffirms Hold Rating for Oncomed Pharmaceuticals (OMED)
www.americanbankingnews.com - March 9 at 9:04 PM |
| Oncomed Pharmaceuticals (OMED) Posts Earnings Results, Beats Expectations By $0.59 EPS
www.americanbankingnews.com - March 9 at 4:27 PM |
| OncoMed Announces Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights
finance.yahoo.com - March 9 at 11:54 AM |
| OncoMed tops Street 4Q forecasts
finance.yahoo.com - March 9 at 11:54 AM |
| When Can We Expect A Profit From OncoMed Pharmaceuticals Inc (NASDAQ:OMED)?
finance.yahoo.com - March 9 at 11:54 AM |
| OncoMed Pharmaceuticals Q4 Earnings Preview
finance.yahoo.com - March 8 at 4:12 PM |
| Has OncoMed Pharmaceuticals Inc (NASDAQ:OMED) Improved Earnings Growth In Recent Times?
finance.yahoo.com - March 7 at 4:04 PM |
 | Partner Therapeutics (PTx) Announces the Appointment of Ellen Hukkelhoven Ph.D. and Terry Gould to its Board of Directors
www.bizjournals.com - March 7 at 10:52 AM |
| Brokerages Expect Oncomed Pharmaceuticals Inc (OMED) Will Post Quarterly Sales of $5.10 Million
www.americanbankingnews.com - March 3 at 1:22 PM |
| Oncomed Pharmaceuticals Inc (OMED) Expected to Post Earnings of -$0.31 Per Share
www.americanbankingnews.com - March 1 at 11:45 AM |
| Oncomed Pharmaceuticals (OMED) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - March 1 at 2:08 AM |
| Oncomed Pharmaceuticals Inc (OMED) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 28 at 11:57 AM |
| Oncomed Pharmaceuticals' (OMED) "Neutral" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - February 24 at 3:32 PM |
| OncoMed Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights on March 8th, 2018
finance.yahoo.com - February 23 at 10:19 AM |
| Why You Need To Look At This Factor Before Buying OncoMed Pharmaceuticals Inc (NASDAQ:OMED)
finance.yahoo.com - February 21 at 10:54 AM |
OncoMed Pharmaceuticals (NASDAQ:OMED) SEC Filings
This page is loading this company's SEC Filings. Please wait...
OncoMed Pharmaceuticals (NASDAQ:OMED) Income Statement, Balance Sheet and Cash Flow Statement
OncoMed Pharmaceuticals (NASDAQ OMED) Stock Chart for Monday, May, 21, 2018
Loading chart…
